Novelix Pharmaceuticals Ltd — Board Meeting, 24-06-2025: Board Meeting

Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956

(NOVELIX | 536565 | INE314I01036)

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat

Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.trimurthidrugs.com

Date: 24th June, 2025

To,

The Deputy Manager

Department of Corporate Services

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai-400001.

Sub: Outcome of Board Meeting held on Tuesday, 24th June, 2025 pursuant to Regulation

30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code: 536565

Scrip Id: NOVELIX

Respected Sir/ Madam,

This is to inform that Board of Directors of the Company in their meeting held on Tuesday,

24th June, 2025 at the registered office of the company i.e. H No: 3-6-237/610, Flat No: 610,

6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar,

Hyderabad, Telangana- 500029, which commenced at 5:00 P.M. has Considered and approved

the allotment of 2985000 equity shares of the face value of Rs. 10 each at an issue price of Rs.

20/- each (including a premium of Rs. 10/- per share), fully paid-up upon exercising the option

available with warrant holders (person belonging to promoter & non promoter category who

have paid Rs. 15 per warrant i.e. the remaining 75% of issue price) to convert 2985000 warrants

out of 1,50,00,000 warrants allotted on 10th January, 2025 on preferential basis through Special

resolution passed by the shareholders of the Company at the Extra-Ordinary General Meeting

on November 18th 2024 and In-Principle approval received from the BSE Limited on December

31st 2024.

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular

No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is attached herewith as annexure I.

The Meeting was concluded at 05:30 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your

website.

Thanking you,

Yours Faithfully,

For Novelix Pharmaceuticals Limited

Venkateshwarlu Pulluru

(Whole-time director)

DIN: 02076871

----------------Page (0) Break----------------

Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956

(NOVELIX | 536565 | INE314I01036)

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat

Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.trimurthidrugs.com

Annexure I

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with

Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015:

1. Type of securities proposed to be issued- Equity Shares upon conversion of Warrants.

2. Type of Issuance- Preferential issue to Promoter & Non promoters.

3. Total Number of Equity Shares Allotted: 2985000 Equity Shares issued upon conversion

of equal number of Warrants (face value of Rs. 10/-) @ Rs. 20 each.

4. Names of the allottees of Equity Shares:

Sr. No. Name of the Allottees No. of Equity Shares allotted

Strategic Investors (Promoter Group)

1. Narahari Belide 200000

Strategic Investors (Non- Promoters)

2. Mallela Venkataramana Reddy 1500000

3. Chintalapati Sesha Sai Nikhil 200,000

4. KS Swetha 200,000

5. Palakurthi Rakesh 100,000

6. Prasad Panchagnula V L N S V 150,000

7. Rajesh Kommera 100,000

8. N V D Sai Lakshmi Palakurthi 100,000

9. Pallapothu Sivakrishna 50,000

10. Puranam Surender Kumar 70,000

11. Archana Elapavuluri 50,000

12. Sudheer Karna Kankanala 50,000

13. Kanakapur Srinivasa Rao Seshagir Rao 50,000

14. Uday Chandrika Chirala 50,000

15. Palakurthi Renuka 40,000

16. Puranam Suneel Kumar 30,000

17. Nagubandi L Kusuma 25,000

18. Aedula Srikanth 10,000

19. Bhoomika Choudhary 10,000

5. Post Allotment of Equity Shares:

 Outcome of Subscription- The Company has received Rs. 44,775,000.00/- (Rupees Four Crore

Forty-Seven Lakhs Seventy-Five Thousand) on allotment of 2985000 (Twenty-Nine Lakhs

Eighty-Five Thousand) Equity Shares upon conversion of 2985000 warrants out of 1,50,00,000

warrants allotted on 10th January, 2025. (Issue price of Rs. 20/- per equity share)

 Issue Price/ Allotted Price- Issue price of Rs. 20/- each (Face Value Rs. 10/- each + Premium Rs.

10/- each)

 Number of Investors- 19

----------------Page (1) Break----------------

Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956

(NOVELIX | 536565 | INE314I01036)

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6Th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat

Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.trimurthidrugs.com

Consequent to the aforesaid allotment of 2985000 (Twenty-Nine Lakhs Eighty-Five Thousand)

Equity Shares; the paid-up equity capital of the Company has increased from 99,500,000.00/-

consisting of 99,50,000 Equity Shares of Rs. 10/- each to Rs. 12,93,50,000.00/- consisting of

12,935,000 Equity Shares of Rs. 10/- each.

6. In case of convertibles-Intimation on conversion of securities or on lapse of the tenure

of the instrument: Intimation on conversion of securities.

----------------Page (2) Break----------------